Predictors of response to neoadjuvant treatment changes to HER2 status in HER2-positive invasive breast

Liu，Jianlan1; Chen，Daishi2; Hu，Hong3; Zhou，Dongxian3; Hu，Jintao1

2022-05-30

10.19401/j.cnki.1007-3639.2022.05.007

中国癌症杂志   影响因子和分区

1007-3639

Background and purpose: The response of human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer to HER2 targeted neoadjuvant therapy is significant. However, the response is not uniform, and a proportion of patients respond poorly. This study aimed to identify predictors of response in the neoadjuvant treatment and to assess the discordance rate of HER2 status between pre-and post-treatment specimens in HER2-positive breast cancer. Methods: The study group included 110 HER2-positive breast cancer patients treated with neoadjuvant therapy and surgery who were diagnosed from 2019 to 2021 in Shenzhen People’s Hospital. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to detect the expression of HER2 in core needle biopsy specimens. Pathological complete response (pCR) and residual cancer burden (RCB) of surgically resected specimens after neoadjuvant therapy were used to assess the therapy response of patients. HER2, estrogen receptor (ER) and progesterone receptor (PR) status were further assessed in the residual invasive carcinoma present after neoadjuvant therapy. Results: One hundred and ten breast cancer patients were divided into IHC diffuse 3+ group (n=81), heterogeneous 3+ group (n=20), IHC 2+ and FISH amplified (2+FISH+) group (n=9). The pCR rate of HER2 diffuse 3+ group was 54.3%, which was significantly higher compared with heterogeneous 3+ group (5.0%) and 2+FISH+ group (11.1%), and the difference was statistically significant (P＜0.05). RCB categories were higher in heterogeneous 3+ and 2+FISH+ groups. Multivariate analysis showed that HER2 diffuse 3+ was an independent predictor of pCR. Seven cases (11.9%) became HER2-negative, the majority (85.7%) from heterogeneous 3+ and 2+FISH+ groups. Conclusion: HER2 heterogeneity predicts the neoadjuvant therapy response of HER2-positive breast cancer. Evaluation of the heterogeneity of HER2 IHC in biopsy specimens and repeating HER2, ER and PR testing after neoadjuvant treatment should therefore be considered, which will facilitate further management decisions. The patients with HER2 heterogeneity may potentially benefit from the novel antibody-drug conjugate (ADC).

Breast cancer Human epidermal growth factor receptor 2 heterogeneity Neoadjuvant therapy

英语

第一 ; 通讯

2-s2.0-85135561302

Scopus

1.Department of Pathology,Shenzhen People’s Hospital,The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology,Shenzhen,Guangdong Province,518020,China
2.Department of Otorhinolaryngology,Shenzhen People’s Hospital The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,Guangdong Province,518020,China
3.Department of Thyroid and Breast Surgery,Shenzhen People’s Hospital The Second Clinical Medical College,Jinan University,The First Affiliated Hospital,Southern University of Science and Technology),Shenzhen,Guangdong Province,518020,China

Liu，Jianlan,Chen，Daishi,Hu，Hong,et al. Predictors of response to neoadjuvant treatment changes to HER2 status in HER2-positive invasive breast[J]. 中国癌症杂志,2022,32(5):417-426.

Liu，Jianlan,Chen，Daishi,Hu，Hong,Zhou，Dongxian,&Hu，Jintao.(2022).Predictors of response to neoadjuvant treatment changes to HER2 status in HER2-positive invasive breast.中国癌症杂志,32(5),417-426.

Liu，Jianlan,et al."Predictors of response to neoadjuvant treatment changes to HER2 status in HER2-positive invasive breast".中国癌症杂志 32.5(2022):417-426.